During the past decade, Praxis fuer Haematologie und Onkologie conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 4 clinical trials were completed, i.e. on average, 36.4% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 4 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Praxis fuer Haematologie und Onkologie" #1 sponsor was "Celgene" with 4 trials, followed by "Hoffmann-La Roche" with 4 trials sponsored, "German CLL Study Group" with 3 trials sponsored, "German High-Grade Non-Hodgkin's Lymphoma Study Group" with 3 trials sponsored and "University of Heidelberg Medical Center" with 3 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Praxis fuer Haematologie und Onkologie" #1 collaborator was "German CLL Study Group" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator and "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Praxis fuer Haematologie und Onkologie" are "Lymphoma" (3 trials), "Multiple Myeloma" (3 trials), "Chronic Lymphoid Leukemia" (2 trials), "B-cell Chronic Lymphocytic Leukemia" (1 trials) and "Chronic Lymphocytic Leukemia" (1 trials). Many other conditions were trialed in "Praxis fuer Haematologie und Onkologie" in a lesser frequency.

Most popular intervention types in "Praxis fuer Haematologie und Onkologie" are "Drug" (17 trials), "Biological" (5 trials), "Radiation" (3 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Lenalidomide" (5 trials), "Dexamethasone" (3 trials), "Placebo" (3 trials), "cyclophosphamide" (3 trials) and "doxorubicin hydrochloride" (3 trials). Other intervention names were less common.

The vast majority of trials in "Praxis fuer Haematologie und Onkologie" are 17 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Praxis fuer Haematologie und Onkologie". undefined are not yet recruiting, 2 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Praxis fuer Haematologie und Onkologie, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Praxis fuer Haematologie und Onkologie, 1 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".